Compare CCU & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCU | PTGX |
|---|---|---|
| Founded | 1850 | 2006 |
| Country | Chile | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 9.3B |
| IPO Year | 2001 | 2016 |
| Metric | CCU | PTGX |
|---|---|---|
| Price | $11.23 | $143.77 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | $12.00 | ★ $108.23 |
| AVG Volume (30 Days) | 127.0K | ★ 456.7K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.35 |
| Revenue | N/A | N/A |
| Revenue This Year | $7.42 | $874.25 |
| Revenue Next Year | $4.71 | N/A |
| P/E Ratio | ★ $18.35 | $63.06 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.71 | $57.90 |
| 52 Week High | $15.36 | $160.81 |
| Indicator | CCU | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 43.04 | 52.79 |
| Support Level | $11.40 | $141.95 |
| Resistance Level | $11.58 | $160.81 |
| Average True Range (ATR) | 0.32 | 5.37 |
| MACD | -0.07 | -0.89 |
| Stochastic Oscillator | 9.35 | 36.38 |
United Breweries Co Inc is a multi-category beverage company with operations in Chile, Argentina, Bolivia, Colombia, Paraguay and Uruguay. The company is a player in each one of the beverage categories in which it participates in Chile, including beer, soft drinks, mineral and bottled water, juice, wine, cider and pisco, among others. The Company has three operating segment with respect to its revenues in the geographic areas of commercial activity: Chile; International business and Wine. It generates maximum revenue from Chile.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.